Genor Biopharma Holdings Limited stock analysis
Genor Biopharma Holdings Limited (67N0) Stock Price & Analysis
67N0 Stock Chart & Stats
- Day’s Range
- EUR 0.17 - EUR 0.17
- 52-Week Range
- EUR 0.15 - EUR 0.41
- Previous Close
- EUR 0.17
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 360.41M
- Enterprise Value
- EUR 3.62B
- Total Cash (Recent Filing)
- EUR 913.17M
- Total Debt (Recent Filing)
- EUR 1.18B
- Price to Earnings (P/E)
- 4.2
- Beta
- 0.34
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
2025 Profitability Inflection
The sharp 2025 shift to meaningful revenue and solid operating profitability indicates the company has recently converted its biologics activities into an earnings-generating business. If maintained, this higher-margin base can support reinvestment in drug development, manufacturing, and commercialization over the next several quarters.
Positive Cash Generation
Positive operating and free cash flow, together with free cash flow close to reported net income, provides constructive evidence that 2025 profits were supported by cash conversion. This improves the company’s ability to fund operations and development internally rather than relying entirely on external financing.
Meaningful Capital Base
A substantial equity base and moderate debt-to-equity ratio provide a financial foundation for a biologics company whose returns depend on continued development and commercialization investment. This capital position can offer flexibility to support growth initiatives, even though recent borrowing warrants monitoring.
Bears Say
Unproven Earnings Durability
The 2025 earnings improvement follows a long period of inconsistent results, including several years of losses and periods with zero reported revenue. That history makes it difficult to establish a dependable earnings trend, so the company must demonstrate that the recent commercial and profit step-up is repeatable.
Sharp Debt Increase
The substantial move from near-zero debt to roughly 1.49B changes the company’s financial risk profile and introduces greater obligations alongside its recent growth. Even with moderate debt-to-equity overall, higher borrowings can reduce flexibility if profitability or cash generation weakens.
Cash Flow Stability Risk
The 2025 cash-flow improvement is encouraging, but it represents a reversal from several years of materially negative cash generation. Because the company has not yet shown consistent free cash flow across periods, future funding needs and the durability of internally generated cash remain important structural concerns.
Genor Biopharma Holdings Limited News
67N0 FAQ
What was Genor Biopharma Holdings Limited’s price range in the past 12 months?
What is Genor Biopharma Holdings Limited’s market cap?
When is Genor Biopharma Holdings Limited’s upcoming earnings report date?
How were Genor Biopharma Holdings Limited’s earnings last quarter?
Is Genor Biopharma Holdings Limited overvalued?
Does Genor Biopharma Holdings Limited pay dividends?
What is Genor Biopharma Holdings Limited’s EPS estimate?
How many shares outstanding does Genor Biopharma Holdings Limited have?
What happened to Genor Biopharma Holdings Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Genor Biopharma Holdings Limited?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Genor Biopharma Holdings Limited
Edding Genor Group Holdings Limited operates as a biopharmaceutical enterprise, concentrating its efforts on the research, development, and commercialization of therapeutic agents for oncology and autoimmune disorders, both within China and globally. Its key investigational medicines include GB242, an infliximab (Remicade) biosimilar. This drug is purposed for the treatment of various conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric Crohn's disease, and fistulizing Crohn's disease. Another prominent candidate is GB491 (lerociclib), an oral CDK4/6 inhibitor currently undergoing Phase III clinical trials for hormone receptor-positive (HR+)/HER2- breast cancer. Additionally, GB492, a stimulator of interferon genes (STING) agonist, is in Phase 1/2 clinical development, with expectations of synergistic effects when combined with GB226 for solid tumor treatment. The company's pipeline also encompasses GB221, a HER2 monoclonal antibody (mAb) designed to mimic trastuzumab (Herceptin); geptanolimab (GB226), a novel PD-1 mAb; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb, which is in Phase I clinical trials; and GB261, also in Phase I clinical trials for B-cell non-Hodgkin Lymphoma. Furthermore, its product candidates in clinical trials for cancer treatment include GB262, GB264, GB265, and GB266. Founded in 2007, the firm maintains its headquarters in Shanghai, China.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Xin Ni
- Employees
- 1,499
- Website
- www.eddingpharm.com
- Address
- Building 3, Zhuhai, SH, 201203, CN
Genor Biopharma Holdings Limited (67N0) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 5 | 13 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 1 | 0 | 11 |
